ReviewNeuroscience bulletin2014
Brain network markers of abnormal cerebral glucose metabolism and blood flow in Parkinson's disease.
Review in Neuroscience bulletin, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 37 citations in OpenAlex.
- Nuclear Medicine Imaging Biomarkers in Parkinson's Disease: Past, Present, and Future Directions.Medical sciences (Basel, Switzerland) · 2025Review
- Positron Emission Tomography Imaging in Clinical Trials for Parkinson's Disease: Applications of Metabolic Brain Network Approach.Movement disorders : official journal of the Movement Disorder Society · 2025Review
- Clinical and brain functional correlates of instrumental rigidity measurement in Parkinson's disease.Scientific reports · 2025Article
- A longitudinal evaluation of personalized intrinsic network topography and cognitive decline in Parkinson's disease.The European journal of neuroscience · 2024Article
- Alternation of the Rich-Club Organization of Individual Brain Metabolic Networks in Parkinson's Disease.Frontiers in aging neuroscience · 2022Article
- Circuit imaging biomarkers in preclinical and prodromal Parkinson's disease.Molecular medicine (Cambridge, Mass.) · 2021Review
- Neuroimaging evaluation of deep brain stimulation in the treatment of representative neurodegenerative and neuropsychiatric disorders.Bioelectronic medicine · 2021Review
- Radiomics and supervised machine learning in the diagnosis of parkinsonism with FDG PET: promises and challenges.Annals of translational medicine · 2020Article
- Bayesian Network Marker Selection via the Thresholded Graph Laplacian Gaussian Prior.Bayesian analysis · 2020Article
- Brain Functional and Structural Signatures in Parkinson's Disease.Frontiers in aging neuroscience · 2020Article
- HIV-1 infection alters energy metabolism in the brain: Contributions to HIV-associated neurocognitive disorders.Progress in neurobiology · 2019Review
- Functional Alteration of Cerebello-Cerebral Coupling in an Experimental Mouse Model of Parkinson's Disease.Cerebral cortex (New York, N.Y. : 1991) · 2019Article
- Intra- and Inter-scanner Reliability of Scaled Subprofile Model of Principal Component Analysis on ALFF in Resting-State fMRI Under Eyes Open and Closed Conditions.Frontiers in neuroscience · 2018Article
- The Role of Glucagon-Like Peptide 1 (GLP1) in Type 3 Diabetes: GLP-1 Controls Insulin Resistance, Neuroinflammation and Neurogenesis in the Brain.International journal of molecular sciences · 2017Review
- The Unwanted Cell Migration in the Brain: Glioma Metastasis.Neurochemical research · 2017Review
- Neuro-molecular imaging.Neuroscience bulletin · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Neuroimaging of cerebral glucose metabolism and blood flow is ideally suited to assay widely-distributed brain circuits as a result of local molecular events and behavioral modulation in the central nervous system. With the progress in novel analytical methodology, this endeavor has succeeded in unraveling the mechanisms underlying a wide spectrum of neurodegenerative diseases. In particular, statistical brain mapping studies have made significant strides in describing the pathophysiology of Parkinson's disease (PD) and related disorders by providing signature biomarkers to determine the systemic abnormalities in brain function and evaluate disease progression, therapeutic responses, and clinical correlates in patients. In this article, we review the relevant clinical applications in patients in relation to healthy volunteers with a focus on the generation of unique spatial covariance patterns associated with the motor and cognitive symptoms underlying PD. These characteristic biomarkers can be potentially used not only to improve patient recruitment but also to predict outcomes in clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.